Citadel Advisors’s Amedisys AMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-128,947
| Closed | -$12.7M | – | 12677 |
|
|
2025
Q2 | $12.7M | Sell |
128,947
-336,526
| -72% | -$31.8M | ﹤0.01% | 2712 |
|
|
2025
Q1 | $43.1M | Sell |
465,473
-407,489
| -47% | -$37.6M | 0.01% | 1263 |
|
|
2024
Q4 | $79.3M | Buy |
872,962
+268,661
| +44% | +$24.7M | 0.01% | 888 |
|
|
2024
Q3 | $58.3M | Buy |
604,301
+482,720
| +397% | +$47.1M | 0.01% | 1071 |
|
|
2024
Q2 | $11.2M | Buy |
+121,581
| New | +$11.3M | ﹤0.01% | 2644 |
|
|
2024
Q1 | – | Sell |
-4,679
| Closed | -$438K | – | 14495 |
|
|
2023
Q4 | $445K | Sell |
4,679
-64,757
| -93% | -$6.05M | ﹤0.01% | 8361 |
|
|
2023
Q3 | $6.49M | Buy |
69,436
+53,223
| +328% | +$4.92M | ﹤0.01% | 3272 |
|
|
2023
Q2 | $1.48M | Sell |
16,213
-488,021
| -97% | -$40M | ﹤0.01% | 5699 |
|
|
2023
Q1 | $37.1M | Buy |
504,234
+237,826
| +89% | +$20.6M | 0.01% | 1342 |
|
|
2022
Q4 | $22.3M | Buy |
266,408
+79,915
| +43% | +$7.21M | 0.01% | 1853 |
|
|
2022
Q3 | $18.1M | Buy |
186,493
+40,210
| +27% | +$4.79M | ﹤0.01% | 1993 |
|
|
2022
Q2 | $15.4M | Buy |
146,283
+142,512
| +3,779% | +$18.2M | ﹤0.01% | 2134 |
|
|
2022
Q1 | $650K | Sell |
3,771
-12,219
| -76% | -$1.83M | ﹤0.01% | 8751 |
|
|
2021
Q4 | $2.59M | Sell |
15,990
-174,598
| -92% | -$28.1M | ﹤0.01% | 5637 |
|
|
2021
Q3 | $28.4M | Buy |
190,588
+123,798
| +185% | +$25.7M | 0.01% | 1618 |
|
|
2021
Q2 | $16.4M | Sell |
66,790
-1,949
| -3% | -$511K | ﹤0.01% | 2343 |
|
|
2021
Q1 | $18.2M | Sell |
68,739
-51,157
| -43% | -$14.4M | ﹤0.01% | 2089 |
|
|
2020
Q4 | $35.2M | Sell |
119,896
-72,171
| -38% | -$18.5M | 0.01% | 1251 |
|
|
2020
Q3 | $45.4M | Buy |
192,067
+3,735
| +2% | +$849K | 0.01% | 923 |
|
|
2020
Q2 | $37.4M | Buy |
188,332
+145,381
| +338% | +$27.1M | 0.01% | 991 |
|
|
2020
Q1 | $7.88M | Buy |
42,951
+9,748
| +29% | +$1.73M | ﹤0.01% | 2137 |
|
|
2019
Q4 | $5.54M | Sell |
33,203
-6,605
| -17% | -$982K | ﹤0.01% | 2947 |
|
|
2019
Q3 | $5.22M | Sell |
39,808
-35,357
| -47% | -$4.6M | ﹤0.01% | 3055 |
|
|
2019
Q2 | $9.13M | Sell |
75,165
-280,263
| -79% | -$33.3M | ﹤0.01% | 2288 |
|
|
2019
Q1 | $43.8M | Buy |
355,428
+148,613
| +72% | +$18.7M | 0.02% | 768 |
|
|
2018
Q4 | $24.2M | Buy |
206,815
+125,965
| +156% | +$14.8M | 0.01% | 1084 |
|
|
2018
Q3 | $10.1M | Buy |
80,850
+39,292
| +95% | +$4.34M | ﹤0.01% | 2083 |
|
|
2018
Q2 | $3.55M | Sell |
41,558
-3,598
| -8% | -$264K | ﹤0.01% | 3251 |
|
|
2018
Q1 | $2.72M | Sell |
45,156
-110,127
| -71% | -$6.27M | ﹤0.01% | 3272 |
|
|
2017
Q4 | $8.19M | Buy |
155,283
+69,206
| +80% | +$3.65M | 0.01% | 1929 |
|
|
2017
Q3 | $4.82M | Buy |
86,077
+67,834
| +372% | +$3.59M | ﹤0.01% | 2338 |
|
|
2017
Q2 | $1.15M | Sell |
18,243
-7,016
| -28% | -$409K | ﹤0.01% | 3893 |
|
|
2017
Q1 | $1.29M | Sell |
25,259
-7,777
| -24% | -$371K | ﹤0.01% | 3624 |
|
|
2016
Q4 | $1.41M | Buy |
33,036
+24,238
| +275% | +$1.03M | ﹤0.01% | 3384 |
|
|
2016
Q3 | $417K | Buy |
8,798
+4,829
| +122% | +$241K | ﹤0.01% | 5144 |
|
|
2016
Q2 | $200K | Buy |
+3,969
| New | +$200K | ﹤0.01% | 5832 |
|
|
2016
Q1 | – | Sell |
-30,779
| Closed | -$1.19M | – | 6677 |
|
|
2015
Q4 | $1.21M | Buy |
+30,779
| New | +$1.23M | ﹤0.01% | 3349 |
|
|
2015
Q3 | – | Sell |
-40,808
| Closed | -$1.72M | – | 8845 |
|
|
2015
Q2 | $1.62M | Sell |
40,808
-10,876
| -21% | -$339K | ﹤0.01% | 3317 |
|
|
2015
Q1 | $1.39M | Sell |
51,684
-22,821
| -31% | -$644K | ﹤0.01% | 3536 |
|
|
2014
Q4 | $2.19M | Buy |
+74,505
| New | +$1.84M | ﹤0.01% | 2815 |
|
|
2014
Q2 | – | Sell |
-8,615
| Closed | -$122K | – | 7936 |
|
|
2014
Q1 | $128K | Sell |
8,615
-2,653
| -24% | -$40.8K | ﹤0.01% | 5946 |
|
|
2013
Q4 | $165K | Buy |
+11,268
| New | +$181K | ﹤0.01% | 5211 |
|
Other funds holding AMED
IA
MCI
HNB
Citadel Advisors's AMED Position: Q3 2025 in Review
Citadel Advisors sold out of Amedisys (AMED) in Q3 2025, closing a stake of 128,947 shares — an estimated $12.7M sold.
Citadel Advisors first reported a position in AMED in Q4 2013 and held it in 42 quarters. The position peaked at $79.3M in Q4 2024. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.
- Citadel Advisors reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
- Citadel Advisors sold 128,947 Amedisys shares in Q3 2025, an estimated $12.7M.
- Citadel Advisors first reported a position in Amedisys in Q4 2013 and held it in 42 quarters.
- Citadel Advisors's Amedisys position peaked at $79.3M in Q4 2024.
- 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.